8-K: Pacira BioSciences Reports Q3 2025 Results, Lowers Revenue Outlook

Pacira BioSciences reported mixed third-quarter 2025 financial results, including a 6% revenue increase but a lowered full-year revenue guidance, alongside strategic advancements in its non-opioid pain therapy pipeline.

Summary

• Total revenues for Q3 2025 were $179.5 million, a 6% increase from $168.6 million in Q3 2024.
• EXPAREL net product sales grew 9% by volume to $139.9 million in Q3 2025, compared to $132.0 million in Q3 2024.
• GAAP net income was $5.4 million, or $0.12 per share, in Q3 2025, a significant improvement from a GAAP net loss of $143.5 million, or $3.11 per share, in Q3 2024 (which included a $163.2 million goodwill impairment).
• Non-GAAP net income decreased to $31.8 million, or $0.72 per share (basic), in Q3 2025 from $38.2 million, or $0.83 per share (basic), in Q3 2024.
• Adjusted EBITDA was $49.4 million in Q3 2025, down from $54.7 million in Q3 2024.
• The company repurchased 2.0 million shares of common stock for $50.0 million at an average price of $25.30 per share during Q3 2025, with $200.0 million remaining on the authorization.
• Full-year 2025 total revenue guidance was lowered to $725 million to $735 million, from the previous range of $730 million to $750 million.
• Non-GAAP gross margin guidance for full-year 2025 was increased to 80% to 82%, from the previous range of 78% to 80%.
• Patient enrollment concluded in the Phase 2 Part A study of PCRX-201 for osteoarthritis of the knee, with topline results expected near the end of 2026.
• An exclusive worldwide license agreement was signed with AmacaThera for AMT-143, a long-acting non-opioid analgesic, involving an upfront payment of $5.0 million.
• A new EXPAREL patent (No. 12,370,142) was issued, extending exclusivity until July 2044, bringing the total Orange Book listed patents to 21.
• The company received a $23.1 million cash payment plus $5.2 million in statutory interest from the Research Development Foundation following a favorable court judgment regarding previously paid royalties.

Sentiment

Score: 4

Explanation: While there are significant strategic advancements (pipeline, patents, legal win) and GAAP profitability improved, the lowered full-year revenue guidance, decline in non-GAAP profitability metrics, and increased operating expenses present a mixed financial picture. The substantial decrease in cash also raises concerns, leading to a slightly negative overall sentiment.

Positives

• Total revenues increased by 6% year-over-year in Q3 2025 to $179.5 million.
• EXPAREL net product sales volume grew by 9% in Q3 2025.
• GAAP net income turned positive at $5.4 million in Q3 2025, compared to a significant loss in Q3 2024.
• Non-GAAP gross margin guidance for full-year 2025 was increased to 80-82% from 78-80%.
• Patient enrollment concluded for the Phase 2 Part A study of PCRX-201, advancing a key pipeline asset.
• Secured an exclusive worldwide license for AMT-143, expanding the non-opioid pain therapy pipeline.
• A new EXPAREL patent (No. 12,370,142) was issued, extending exclusivity until July 2044, strengthening intellectual property.
• Received a favorable legal judgment resulting in a $23.1 million cash payment and $5.2 million in statutory interest.
• Repurchased 2.0 million shares of common stock for $50.0 million, demonstrating commitment to shareholder returns.

Negatives

• Full-year 2025 total revenue guidance was lowered to $725 million to $735 million, from the previous range of $730 million to $750 million.
• Non-GAAP net income decreased to $31.8 million in Q3 2025 from $38.2 million in Q3 2024.
• Adjusted EBITDA decreased to $49.4 million in Q3 2025 from $54.7 million in Q3 2024.
• Research and development (R&D) expenses increased to $26.0 million in Q3 2025 from $19.1 million in Q3 2024.
• Selling, general and administrative (SG&A) expenses increased to $91.8 million in Q3 2025 from $74.3 million in Q3 2024.
• Recognized a $25.9 million impairment of acquired in-process research and development (IPR&D) related to ZILRETTA for OA of the shoulder.
• Cash, cash equivalents and available-for-sale investments decreased significantly to $246.3 million at the end of Q3 2025 from $484.6 million at the end of 2024.
• EXPAREL sales volume growth was partially offset by a shift in vial mix and discounting associated with a new GPO partnership.

Risks

• Failure to realize the anticipated benefits and synergies from the acquisition of GQ Bio Therapeutics GmbH.
• Risks associated with acquisitions, such as integration difficulties, higher costs, or unfulfilled expected benefits.
• Challenges related to manufacturing and the supply chain.
• Impact of global and United States economic conditions, including tariffs, inflation, and rising interest rates.
• Uncertainty regarding the success of sales and manufacturing efforts for EXPAREL, ZILRETTA, and iovera.
• Variability in the rate and degree of market acceptance of EXPAREL, ZILRETTA, and iovera.
• Ability to accurately assess and serve the size and growth of potential markets for products.
• Risks associated with expanding the use of products to additional indications and the timing and success of related clinical trials for all product candidates, including PCRX-201.
• Uncertainty regarding the commercial success of EXPAREL, ZILRETTA, and iovera.
• Timing and success of United States Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s.
• Timing and success of European Medicines Agency Marketing Authorization Applications.
• Ability to evaluate, develop, and pursue additional product candidates utilizing proprietary multivesicular liposome (pMVL) drug delivery technology.
• Approval of the commercialization of products in other jurisdictions.
• Outcomes of any litigation.
• Recoverability of deferred tax assets.
• Assumptions associated with contingent consideration payments and estimated future cash flows for fair value determination.
• Anticipated funding or benefits of the share repurchase program may not materialize as expected.

Future Outlook

The company is executing its '5x30' growth strategy, aiming to expand leadership in musculoskeletal pain and adjacencies. It expects to report topline results from the Phase 2 Part A study of PCRX-201 near the end of 2026. Full-year 2025 total revenue guidance has been lowered to $725 million to $735 million, while non-GAAP gross margin guidance has been increased to 80% to 82%. Non-GAAP R&D and SG&A expense guidance ranges have also been adjusted upwards. The company continues to innovate with additional EXPAREL patents forthcoming and is advancing its gene therapy platform for future product candidates.

Management Comments

• "Pacira delivered another quarter of strong execution across our corporate, clinical, and commercial initiatives, underscoring the momentum behind our 5x30 growth strategy."
• "With accelerating topline growth, expanding market access, and meaningful pipeline advancements, including the in-licensing of AMT-143, we believe we are well positioned to expand our leadership in musculoskeletal pain and adjacencies."
• "I'm proud of our team's continued focus and discipline, which are driving innovation, improving patient outcomes, and creating long-term value for our shareholders."

Industry Context

Pacira BioSciences positions itself as an industry leader in non-opioid pain therapies, a sector gaining increasing importance due to the opioid crisis and regulatory focus (e.g., NOPAIN Act mentioned as a forward-looking factor). The company's advancements in gene therapy for osteoarthritis (PCRX-201) and long-acting local analgesics (AMT-143) reflect a broader industry trend towards innovative, non-addictive pain management solutions. The acquisition of GQ Bio's high-capacity adenovirus vector platform aims to overcome common gene therapy challenges, potentially giving Pacira a competitive edge in developing therapies for prevalent diseases like osteoarthritis, where PCRX-201 is noted as the first gene therapy to achieve RMAT and ATMP designations. The mention of a generic competitor to EXPAREL in Q3 2024 highlights the competitive landscape and the importance of patent protection in the pharmaceutical industry.

Comparison to Industry Standards

• Pacira's PCRX-201 is noted as the first gene therapy to achieve Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA and Advanced Therapy Medicinal Products (ATMP) designation from the European Medicines Agency in osteoarthritis of the knee, indicating a leading position in this specific therapeutic area compared to other gene therapy developers.
• The company's focus on non-opioid pain therapies aligns with global healthcare trends and regulatory initiatives (like the NOPAIN Act in the U.S.) aimed at reducing opioid dependence, positioning its product portfolio (EXPAREL, ZILRETTA, iovera) favorably against traditional opioid-based pain management solutions.
• The acquisition of GQ Bio's high-capacity adenovirus (HCAd) vector platform is presented as a solution to challenges faced by other gene therapy approaches (e.g., AAV vectors) in terms of delivery efficiency, dose levels, and manufacturing cost, suggesting a potential competitive advantage in gene therapy development.

Legal Proceedings

• Settlement of patent infringement suits against Fresenius Kabi USA, LLC, eVenus Pharmaceuticals Laboratories, Inc., and Jiangsu Hengrui Pharmaceuticals Co., Ltd., resulting in $7.0 million of legal settlement costs in the nine months ended September 30, 2025.
• Favorable judgment from the U.S. District Court for the District of Nevada requiring the Research Development Foundation (RDF) to repay $23.1 million in royalties on EXPAREL sales, plus an additional $5.2 million in statutory interest, received in Q3 2025.

Stakeholder Impact

• **Shareholders:** Mixed impact due to lowered revenue guidance and decreased non-GAAP profitability, offset by strategic pipeline advancements, patent extension, a significant legal win, and ongoing share repurchase program.
• **Employees:** Negative impact for employees affected by the reduction in force in July 2025 due to manufacturing efficiencies; positive impact for 18 new employees receiving inducement awards.
• **Customers/Patients:** Positive impact from continued development and commercialization of innovative non-opioid pain therapies (EXPAREL, ZILRETTA, iovera, PCRX-201, AMT-143) aimed at improving patient outcomes.
• **Creditors:** Positive impact from the repayment of the 0.75% convertible senior notes due 2025 in cash, reducing debt obligations.

Next Steps

• Report topline results from Part A of the Phase 2 ASCEND study of PCRX-201 near the end of 2026.
• Continue to innovate with additional EXPAREL patents forthcoming.
• Execute on the 5x30 growth strategy to expand leadership in musculoskeletal pain and adjacencies.
• Monitor the progress of AMT-143 development and potential future milestone payments and royalties.
• Manage the remaining $200.0 million share repurchase authorization, which expires December 31, 2026.

Key Dates

Recommendation

While Pacira BioSciences demonstrates strategic progress with pipeline advancements, strengthened patent protection, and a significant legal victory, the revised full-year revenue guidance is a downgrade, and non-GAAP profitability metrics (net income, adjusted EBITDA) have declined year-over-year. The substantial decrease in cash and increased operating expenses are also notable concerns. Given these mixed signals, a 'Hold' recommendation is appropriate for a seasoned investor, allowing time to observe the execution of the '5x30' growth strategy and assess if financial performance stabilizes or improves in subsequent quarters before making further investment decisions.

Keywords

Pacira BioSciences, PCRX, Q3 2025 Earnings, Financial Results, Non-opioid Pain Therapy, EXPAREL, ZILRETTA, iovera, PCRX-201, AMT-143, Osteoarthritis, Postsurgical Pain, Gene Therapy, Biotechnology, Pharmaceuticals, SEC Filing, 8-K, Guidance, Patent, Share Repurchase